Skip to content

Multisystem Atrophy - Parkinsonian Type (MSA-P)

Summary

fleuron

  • MSA-P is a neurodegenerative disorder characterised by parkinsonian features, autonomic dysfunction, and cerebellar ataxia
  • Pathologically, it involves α-synuclein accumulation in oligodendrocytes and neuronal loss in multiple brain regions
  • Imaging reveals characteristic patterns of atrophy and signal changes in the basal ganglia, cerebellum, and brainstem

Pathophysiology

  • Accumulation of α-synuclein in glial cytoplasmic inclusions (GCIs) in oligodendrocytes
  • Neuronal loss and gliosis in:
    • Substantia nigra
    • Striatum
    • Globus pallidus
    • Pontine nuclei
    • Inferior olivary nuclei
    • Cerebellar Purkinje cells
  • Degeneration of autonomic nuclei in the brainstem and spinal cord

Demographics

  • Typical onset: 50-60 years of age
  • Slight male predominance (1.3:1)
  • Estimated prevalence: 3-4 per 100,000 population
  • More common in Caucasian populations

Diagnosis

  • Clinical features:
    • Parkinsonism (bradykinesia, rigidity, postural instability)
    • Autonomic dysfunction (orthostatic hypotension, urinary incontinence, erectile dysfunction)
    • Poor response to levodopa therapy
  • Diagnostic criteria:
    • Probable MSA-P: Parkinsonism + autonomic failure/urinary dysfunction
    • Possible MSA-P: Parkinsonism + autonomic dysfunction or cerebellar syndrome

Imaging

  • MRI findings:
    • Putaminal atrophy with T2 hypointensity
    • "Hot cross bun" sign in pons (T2/FLAIR hyperintensity)
    • Cerebellar atrophy
    • "Putaminal rim" sign (T2 hyperintensity at lateral putaminal border)
  • DaTSCAN:
    • Reduced striatal dopamine transporter uptake
  • FDG-PET:
    • Hypometabolism in striatum, brainstem, and cerebellum

panels-1

  • 55-year-old female with left sided parkinsonism and orthostatic systoms.

panels-1

  • 80-year-old patient presented with asymmetric parkinsonism (left > right) with freezing and early falls with poor response to levodopa.
  • MRI showed putaminal atrophy, susceptibility artefact and T2-hyperintensity along the lateral aspect of the putamina.
  • DaTscan showed markedly reduced tracer uptake in the putamina bilaterally.

panels-1

  • 60-year-old patient with a bilateral tremor.
  • T2 weighted imaging shows the lateral rim sign and mild putaminal volume loss.
  • While SWI was not performed, low signal was seen in the putamina on EPI DWI, which is sensitive to susceptibility artefact.

Treatment

  • Symptomatic management:
    • Levodopa for parkinsonism (often with limited response)
    • Fludrocortisone or midodrine for orthostatic hypotension
    • Anticholinergics for urinary symptoms
  • Supportive care:
    • Physical therapy
    • Occupational therapy
    • Speech therapy
  • No disease-modifying treatments currently available
  • Ongoing research into neuroprotective strategies and α-synuclein-targeted therapies

Differential diagnosis

Differential Diagnosis Distinguishing Feature
Parkinson's Disease Poor response to levodopa; early autonomic dysfunction in MSA-P
Progressive Supranuclear Palsy Vertical gaze palsy in PSP; more prominent cerebellar signs in MSA-P
Corticobasal Degeneration Asymmetric limb apraxia and cortical sensory loss in CBD; more symmetric presentation in MSA-P
Dementia with Lewy Bodies Early cognitive decline and visual hallucinations in DLB; more prominent autonomic dysfunction in MSA-P
Multiple System Atrophy - Cerebellar Type Predominant cerebellar ataxia in MSA-C; more prominent parkinsonism in MSA-P
Vascular Parkinsonism Stepwise progression and evidence of cerebrovascular disease on imaging in vascular parkinsonism
Drug-Induced Parkinsonism History of causative medication use; typically resolves after drug discontinuation
Normal Pressure Hydrocephalus Triad of gait disturbance, urinary incontinence, and cognitive decline; ventricular enlargement on imaging